CN115697307A - 包含达普司他的制剂 - Google Patents

包含达普司他的制剂 Download PDF

Info

Publication number
CN115697307A
CN115697307A CN202180043608.0A CN202180043608A CN115697307A CN 115697307 A CN115697307 A CN 115697307A CN 202180043608 A CN202180043608 A CN 202180043608A CN 115697307 A CN115697307 A CN 115697307A
Authority
CN
China
Prior art keywords
immediate release
tablet
release tablet
dose
hemoglobin concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180043608.0A
Other languages
English (en)
Chinese (zh)
Inventor
S.查托拉杰
S.R.克洛伊
J.A.麦克劳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of CN115697307A publication Critical patent/CN115697307A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN202180043608.0A 2020-06-19 2021-06-17 包含达普司他的制剂 Pending CN115697307A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063041403P 2020-06-19 2020-06-19
US63/041,403 2020-06-19
US202063043292P 2020-06-24 2020-06-24
US63/043,292 2020-06-24
PCT/EP2021/066386 WO2021255159A1 (en) 2020-06-19 2021-06-17 Formulation comprising daprodustat

Publications (1)

Publication Number Publication Date
CN115697307A true CN115697307A (zh) 2023-02-03

Family

ID=76730508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043608.0A Pending CN115697307A (zh) 2020-06-19 2021-06-17 包含达普司他的制剂

Country Status (7)

Country Link
US (1) US20230225977A1 (https=)
EP (1) EP4167967A1 (https=)
JP (1) JP7797425B2 (https=)
CN (1) CN115697307A (https=)
BR (1) BR112022024533A2 (https=)
CA (1) CA3180509A1 (https=)
WO (1) WO2021255159A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025087207A1 (zh) * 2023-10-24 2025-05-01 杭州安道药业有限公司 含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024521491A (ja) * 2021-06-18 2024-05-31 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド ダプロデュスタットおよびその前駆体の新規な製造方法
WO2024257063A1 (en) * 2023-06-16 2024-12-19 Glenmark Life Sciences Limited Solid dispersion of daprodustat and a process for the preparation thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101773498A (zh) * 2009-12-30 2010-07-14 青岛黄海制药有限责任公司 一种含有非布司他的口服缓控释制剂及其制备方法
CN108135854A (zh) * 2015-06-30 2018-06-08 基因泰克公司 含有药物的立即释放片剂和用于形成片剂的方法
WO2019052133A1 (zh) * 2017-09-15 2019-03-21 苏州科睿思制药有限公司 Gsk1278863的晶型及其制备方法和制药用途
WO2020102302A1 (en) * 2018-11-15 2020-05-22 Teva Pharmaceuticals International Gmbh Solid state forms of daprodustat and process for preparation thereof
CN111278433A (zh) * 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CA2937365C (en) * 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
PH12018000227A1 (en) * 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
CN112955130A (zh) * 2018-10-30 2021-06-11 佩洛通治疗公司 包含取代茚满的固体分散体和药物组合物及其制备和使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101773498A (zh) * 2009-12-30 2010-07-14 青岛黄海制药有限责任公司 一种含有非布司他的口服缓控释制剂及其制备方法
CN108135854A (zh) * 2015-06-30 2018-06-08 基因泰克公司 含有药物的立即释放片剂和用于形成片剂的方法
WO2019052133A1 (zh) * 2017-09-15 2019-03-21 苏州科睿思制药有限公司 Gsk1278863的晶型及其制备方法和制药用途
CN111278433A (zh) * 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2020102302A1 (en) * 2018-11-15 2020-05-22 Teva Pharmaceuticals International Gmbh Solid state forms of daprodustat and process for preparation thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTINE K. BAILEY 等: "A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis", BMC NEPHROLOGY, vol. 20, pages 372 *
LOUIS HOLDSTOCK 等: "Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 27, no. 4, pages 1234 - 1244, XP055619120, DOI: 10.1681/ASN.2014111139 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025087207A1 (zh) * 2023-10-24 2025-05-01 杭州安道药业有限公司 含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用

Also Published As

Publication number Publication date
JP2023532223A (ja) 2023-07-27
CA3180509A1 (en) 2021-12-23
US20230225977A1 (en) 2023-07-20
JP7797425B2 (ja) 2026-01-13
BR112022024533A2 (pt) 2022-12-27
WO2021255159A1 (en) 2021-12-23
EP4167967A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
JP7627302B2 (ja) パルボシクリブの固形剤形
JP7797425B2 (ja) ダプロデュスタットを含んでなる処方物
MX2012000892A (es) Formas de dosificacion de citrato ferrico.
WO2008027600A2 (en) Imatinib compositions
KR20210045404A (ko) 다낭성 난소 증후군 치료에 유용한 활성 약학적 성분들의 삼중 조합의 즉시 방출 제제
JP6630229B2 (ja) レベチラセタム含有医薬組成物及びその製造方法
CN108366982A (zh) 依氟鸟氨酸和舒林酸，固定剂量的组合制剂
TWI903066B (zh) 包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之口服用複合調配物
TWI356711B (en) Saquinavir mesylate oral dosage form
JP7264711B2 (ja) レベチラセタム含有医薬組成物の製造方法
CN113368032A (zh) 药物组合物、口服固体制剂及其制备方法和用途
CN113368067A (zh) 制备用于降低血液尿酸水平的口服药物片剂的方法
WO2005089720A1 (en) Valsartan tablets and the process for the preparation thereof
JP2021518422A (ja) レナリドミドを含む医薬組成物
JP6328138B2 (ja) Ｎ−［５−［２−（３，５−ジメトキシフェニル）エチル］−２ｈ−ピラゾール−３−イル］−４−［（３ｒ，５ｓ）−３，５−ジメチルピペラジン−１−イル］ベンズアミドの医薬製剤
WO2022042646A1 (zh) 盐酸鲁拉西酮组合物及其制备方法
WO2022115055A1 (en) Immediate release composition of favipiravir
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
EP2554164B1 (en) Pharmaceutical formulation based on ibuprofen and codeine having having improved stability
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태
TR2023006078T2 (tr) Favi̇pi̇ravi̇ri̇n hemen salimli kompozi̇syonu
EA049988B1 (ru) Лекарственная форма для перорального применения, содержащая 1-(3-циано-1-изопропил-индол-5-ил)пиразол-4-карбоновую кислоту
JP2006257068A (ja) 高含量塩酸テルビナフィン錠剤およびその製造方法
CA2709624A1 (en) Immediate release dosage form of bosentan and process of manufacturing such
WO2013050339A1 (en) Pharmaceutical compositions of antihypertensives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230203